Innate Pharma (NASDAQ:IPHA) Releases Quarterly Earnings Results, Beats Estimates By $0.17 EPS

Innate Pharma (NASDAQ:IPHA) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.17, FiscalAI reports. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $1.96 million.

Here are the key takeaways from Innate Pharma’s conference call:

• FDA clearance received for the TELLOMAK 3 Phase III lacutamab trial in CTCL with initiation targeted in H2 2026, though start is contingent on securing non‑dilutive financing or partnership/royalty deals.
• IPH4502 (Nectin‑4 TOP1 ADC) has shown preliminary antitumor activity — including in urothelial cancer post‑enfortumab vedotin — with dose exploration ongoing and a favorable safety profile supporting potential best‑in‑class positioning.
• Monalizumab PACIFIC‑9 has completed enrollment (~999 patients) with primary endpoint readout expected in H2 2026, and the AstraZeneca partnership provides meaningful upside (up to $1.275bn in milestones, $450m received) plus royalties/profit‑share potential.
• Financial runway is limited: year‑end cash of EUR 44.8 million gives visibility only through end‑Q3 2026 under the current plan, implying near‑term need for additional funding to advance late‑stage programs.
• IPH5201 (anti‑CD39) MATISSE Phase II interim results were selected for an AACR oral presentation, which could validate the target biology and influence AstraZeneca’s option/expansion decisions for the program.

Innate Pharma Trading Up 0.4%

Shares of Innate Pharma stock traded up $0.01 during trading hours on Thursday, hitting $1.29. 16,790 shares of the company’s stock traded hands, compared to its average volume of 19,602. Innate Pharma has a 12-month low of $1.17 and a 12-month high of $2.63. The company has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $1.82.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on IPHA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. BTIG Research initiated coverage on shares of Innate Pharma in a report on Thursday, March 12th. They set a “buy” rating and a $8.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Institutional Trading of Innate Pharma

A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC purchased a new position in Innate Pharma in the fourth quarter valued at about $36,000. OLD Mission Capital LLC purchased a new stake in shares of Innate Pharma during the 4th quarter worth approximately $50,000. Finally, Jane Street Group LLC bought a new stake in shares of Innate Pharma in the 4th quarter worth approximately $162,000. Hedge funds and other institutional investors own 0.16% of the company’s stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.